KO Just Hit an All-Time High. Then a Ransomware Attack Hit Back.
Coca-Cola's bull case is intact, but two major wildcards are about to get priced in.
Coca-Cola's bull case is intact, but two major wildcards are about to get priced in.
The CFO already told you Q2 billing growth is running above a three-year high.
85% revenue growth and a Rule of 40 score of 145% meet the market's hardest question.
A rare disease dealmaker just bought its way into a new disease category with $5B in peak revenue potential.
The market is pricing in failure. The data is telling a different story.
An 86% EPS beat today just made insurance the most interesting trade in the market.
IBM's warning about enterprise cyber distraction just handed PANW its clearest catalyst yet.
A Meta nuclear PPA and record Q1 adjusted EBITDA are not yet in the price.
A $10B Crinetics deal, a fifth commercial pillar, and Q2 earnings that will define the acquisition thesis.
Record profit, a $265B US bet, and a market asking the wrong question.